Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study
- PMID: 25133488
- DOI: 10.1001/jamainternmed.2014.3384
Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study
Abstract
Importance: Hospitalization for acute medical illness is associated with increased risk of venous thromboembolism (VTE). Although efforts designed to increase use of pharmacologic VTE prophylaxis are intended to reduce hospital-associated VTE, whether higher rates of prophylaxis reduce VTE in medical patients is unknown.
Objective: To examine the association between pharmacologic VTE prophylaxis rates and hospital-associated VTE.
Design, setting, and participants: Retrospective, multicenter cohort study conducted at 35 Michigan hospitals participating in a statewide quality collaborative from January 1, 2011, through September 13, 2012. Trained medical record abstractors at each hospital collected data from 31 260 general medical patients. Use of VTE prophylaxis on admission, VTE risk factors, and VTE events 90 days after hospital admission were recorded using a combination of medical record review and telephone follow-up. Hospitals were grouped into tertiles of performance based on rate of pharmacologic prophylaxis use on admission for at-risk patients.
Main outcomes and measures: Association between hospital performance and time to development of VTE within 90 days of hospital admission.
Results: A total of 14 563 of 20 794 patients (70.0%) eligible for pharmacologic prophylaxis received prophylaxis on admission. The rates of pharmacologic prophylaxis use at hospitals in the high-, moderate-, and low-performance tertiles were 85.8%, 72.6%, and 55.5%, respectively. A total of 226 VTE events occurred during 1 765 449 days of patient follow-up. Compared with patients at hospitals in the highest-performance tertile, the hazard of VTE in patients at hospitals in moderate-performance (hazard ratio, 1.10; 95% CI, 0.74-1.62) and low-performance (hazard ratio, 0.96, 95% CI, 0.63-1.45) tertiles did not differ after adjusting for potential confounders. Results remained robust when examining mechanical prophylaxis, prophylaxis use throughout the hospitalization, and subsequent inpatient stays after discharge from the index hospitalization.
Conclusions and relevance: The occurrence of 90-day VTE in medical patients after hospitalization is low. Patients who receive care at hospitals that have lower rates of pharmacologic prophylaxis do not have higher adjusted hazards of VTE, even after accounting for individual receipt of pharmacologic prophylaxis. Efforts to increase rates of pharmacologic VTE prophylaxis in hospitalized medical patients may not substantively reduce this adverse outcome.
Comment in
-
Venous thromboembolism prophylaxis for medical patients: who needs it?JAMA Intern Med. 2014 Oct;174(10):1585-6. doi: 10.1001/jamainternmed.2014.3357. JAMA Intern Med. 2014. PMID: 25133537 No abstract available.
Similar articles
-
Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.JAMA Netw Open. 2021 Jun 1;4(6):e2111788. doi: 10.1001/jamanetworkopen.2021.11788. JAMA Netw Open. 2021. PMID: 34115129 Free PMC article.
-
Venous Thromboembolism Prophylaxis and Risk in the Inpatient and Outpatient Continuum of Care Among Hospitalized Acutely Ill Patients in the US: A Retrospective Analysis.Adv Ther. 2019 Jan;36(1):59-71. doi: 10.1007/s12325-018-0846-2. Epub 2018 Dec 12. Adv Ther. 2019. PMID: 30543037
-
Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims.Clin Cardiol. 2011 Nov;34(11):682-8. doi: 10.1002/clc.20986. Epub 2011 Nov 6. Clin Cardiol. 2011. PMID: 22057910 Free PMC article.
-
Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.Cochrane Database Syst Rev. 2013 Jul 16;(7):CD008201. doi: 10.1002/14651858.CD008201.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2018 Apr 24;4:CD008201. doi: 10.1002/14651858.CD008201.pub3. PMID: 23861035 Updated. Review.
-
Prevention of venous thromboembolism in the hospitalized medical patient.Cleve Clin J Med. 2008 Apr;75 Suppl 3:S7-16. doi: 10.3949/ccjm.75.suppl_3.s7. Cleve Clin J Med. 2008. PMID: 18494223 Review.
Cited by
-
Impact of Clinical Decision Support with Mandatory versus Voluntary Venous Thromboembolism Risk Assessment in Hospitalized Patients.TH Open. 2024 Sep 12;8(3):e317-e328. doi: 10.1055/s-0044-1790519. eCollection 2024 Jul. TH Open. 2024. PMID: 39268041 Free PMC article.
-
What Constitutes High Risk for Venous Thromboembolism? Comparing Approaches to Determining an Appropriate Threshold.medRxiv [Preprint]. 2024 Sep 1:2024.08.30.24312871. doi: 10.1101/2024.08.30.24312871. medRxiv. 2024. PMID: 39252910 Free PMC article. Preprint.
-
Universal EHRs Clinical Decision Support for Thromboprophylaxis in Medical Inpatients: A Cluster Randomized Trial.JACC Adv. 2023 Sep 13;2(8):100597. doi: 10.1016/j.jacadv.2023.100597. eCollection 2023 Oct. JACC Adv. 2023. PMID: 38938337 Free PMC article.
-
The potential use of artificial intelligence for venous thromboembolism prophylaxis and management: clinician and healthcare informatician perspectives.Sci Rep. 2024 May 26;14(1):12010. doi: 10.1038/s41598-024-62535-9. Sci Rep. 2024. PMID: 38796561 Free PMC article.
-
Venous thromboembolism performance measurement in the United States: An evolving landscape with many stakeholders.J Hosp Med. 2024 Sep;19(9):827-840. doi: 10.1002/jhm.13385. Epub 2024 May 21. J Hosp Med. 2024. PMID: 38770952 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
